Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Treating cancer by targeting a weakness.

Brody LC.

N Engl J Med. 2005 Sep 1;353(9):949-50. No abstract available.

PMID:
16135843
2.

Targeting the DNA damage response in oncology: past, present and future perspectives.

Basu B, Yap TA, Molife LR, de Bono JS.

Curr Opin Oncol. 2012 May;24(3):316-24. doi: 10.1097/CCO.0b013e32835280c6. Review.

PMID:
22476188
3.

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Sandhu SK, Yap TA, de Bono JS.

Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021. Review.

PMID:
19926276
4.

DNA repair deficiency as a therapeutic target in cancer.

Martin SA, Lord CJ, Ashworth A.

Curr Opin Genet Dev. 2008 Feb;18(1):80-6. doi: 10.1016/j.gde.2008.01.016. Epub 2008 Mar 14. Review.

PMID:
18343102
5.

[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].

Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.

Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. Review. Polish.

6.

Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers.

Kinsella TJ.

Clin Cancer Res. 2009 Mar 15;15(6):1853-9. doi: 10.1158/1078-0432.CCR-08-1307. Epub 2009 Feb 24. Review.

7.

Targeted therapy for cancer using PARP inhibitors.

Lord CJ, Ashworth A.

Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016. Review.

PMID:
18644251
8.

Strategies for targeting the DNA damage response for cancer therapeutics.

Zhang D, Wang HB, Brinkman KL, Han SX, Xu B.

Chin J Cancer. 2012 Aug;31(8):359-63. doi: 10.5732/cjc.012.10087. Epub 2012 Jun 14. Review.

9.

The clinical development of inhibitors of poly(ADP-ribose) polymerase.

Calvert H, Azzariti A.

Ann Oncol. 2011 Jan;22 Suppl 1:i53-9. doi: 10.1093/annonc/mdq667. Review.

PMID:
21285153
10.

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.

Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, Pérez JM.

Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):39-53. Review.

PMID:
18221025
11.

[PARP inhibitors--theoretical basis and clinical application].

Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.

Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.

12.

PARP inhibitors for cancer therapy.

Curtin NJ.

Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. Review.

PMID:
15836799
13.

PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H.

Acta Clin Belg. 2011 Jan-Feb;66(1):2-9. Review.

PMID:
21485757
14.

Targeting the DNA Damage Response in Cancer.

O'Connor MJ.

Mol Cell. 2015 Nov 19;60(4):547-60. doi: 10.1016/j.molcel.2015.10.040. Review.

15.

Drugging the Cancers Addicted to DNA Repair.

Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx059. Review.

16.

Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.

De Luca P, De Siervi A.

Front Biosci (Elite Ed). 2016 Jan 1;8:72-83. Review.

PMID:
26709647
17.

PARP inhibitors: A new era of targeted therapy.

Tangutoori S, Baldwin P, Sridhar S.

Maturitas. 2015 May;81(1):5-9. doi: 10.1016/j.maturitas.2015.01.015. Epub 2015 Feb 7. Review.

PMID:
25708226
18.

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

Carden CP, Yap TA, Kaye SB.

Curr Opin Oncol. 2010 Sep;22(5):473-80. doi: 10.1097/CCO.0b013e32833b5126. Review.

PMID:
20485165
19.

New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response.

Luo Y, Leverson JD.

Expert Rev Anticancer Ther. 2005 Apr;5(2):333-42. Review.

PMID:
15877529
20.

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.

Annunziata CM, O'Shaughnessy J.

Clin Cancer Res. 2010 Sep 15;16(18):4517-26. doi: 10.1158/1078-0432.CCR-10-0526. Epub 2010 Sep 7. Review.

Supplemental Content

Support Center